Literature DB >> 18025108

Caffeine regulates alternative splicing in a subset of cancer-associated genes: a role for SC35.

Jia Shi1, Zhen Hu, Kirk Pabon, Kathleen W Scotto.   

Abstract

Alternative splicing of pre-mRNA contributes significantly to human proteomic complexity, playing a key role in development, gene expression and, when aberrant, human disease onset. Many of the factors involved in alternative splicing have been identified, but little is known about their regulation. Here we report that caffeine regulates alternative splicing of a subset of cancer-associated genes, including the tumor suppressor KLF6. This regulation is at the level of splice site selection, occurs rapidly and reversibly, and is concentration dependent. We have recapitulated caffeine-induced alternative splicing of KLF6 using a cell-based minigene assay and identified a "caffeine response element" within the KLF6 intronic sequence. Significantly, a chimeric minigene splicing assay demonstrated that this caffeine response element is functional in a heterologous context; similar elements exist within close proximity to caffeine-regulated exons of other genes in the subset. Furthermore, the SR splicing factor, SC35, was shown to be required for induction of the alternatively spliced KLF6 transcript. Importantly, SC35 is markedly induced by caffeine, and overexpression of SC35 is sufficient to mimic the effect of caffeine on KLF6 alternative splicing. Taken together, our data implicate SC35 as a key player in caffeine-mediated splicing regulation. This novel effect of caffeine provides a valuable tool for dissecting the regulation of alternative splicing of a large gene subset and may have implications with respect to splice variants associated with disease states.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18025108      PMCID: PMC2223418          DOI: 10.1128/MCB.01345-07

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  58 in total

1.  Exon junction sequences as cryptic splice sites: implications for intron origin.

Authors:  Terrie Sadusky; Andrew J Newman; Nicholas J Dibb
Journal:  Curr Biol       Date:  2004-03-23       Impact factor: 10.834

2.  Serine/arginine-rich protein-dependent suppression of exon skipping by exonic splicing enhancers.

Authors:  El Chérif Ibrahim; Thomas D Schaal; Klemens J Hertel; Robin Reed; Tom Maniatis
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

3.  General and specific functions of exonic splicing silencers in splicing control.

Authors:  Zefeng Wang; Xinshu Xiao; Eric Van Nostrand; Christopher B Burge
Journal:  Mol Cell       Date:  2006-06-22       Impact factor: 17.970

Review 4.  SR proteins and splicing control.

Authors:  J L Manley; R Tacke
Journal:  Genes Dev       Date:  1996-07-01       Impact factor: 11.361

5.  Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread.

Authors:  Goutham Narla; Analisa DiFeo; Shen Yao; Asoka Banno; Eldad Hod; Helen L Reeves; Rui F Qiao; Olga Camacho-Vanegas; Alice Levine; Alexander Kirschenbaum; Andrew M Chan; Scott L Friedman; John A Martignetti
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

6.  The role of exon sequences in splice site selection.

Authors:  A Watakabe; K Tanaka; Y Shimura
Journal:  Genes Dev       Date:  1993-03       Impact factor: 11.361

7.  Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6.

Authors:  Alec C Kimmelman; Rui F Qiao; Goutham Narla; Asoka Banno; Nelson Lau; Paula D Bos; Nelson Nuñez Rodriguez; Bertrand C Liang; Abhijit Guha; John A Martignetti; Scott L Friedman; Andrew M Chan
Journal:  Oncogene       Date:  2004-06-24       Impact factor: 9.867

8.  Identification of alternatively spliced mRNA variants related to cancers by genome-wide ESTs alignment.

Authors:  Lijian Hui; Xin Zhang; Xin Wu; Zhixin Lin; Qingkang Wang; Yixue Li; Gengxi Hu
Journal:  Oncogene       Date:  2004-04-15       Impact factor: 9.867

9.  Recognition of unknown conserved alternatively spliced exons.

Authors:  Uwe Ohler; Noam Shomron; Christopher B Burge
Journal:  PLoS Comput Biol       Date:  2005-07-08       Impact factor: 4.475

10.  Selection of alternative 5' splice sites: role of U1 snRNP and models for the antagonistic effects of SF2/ASF and hnRNP A1.

Authors:  I C Eperon; O V Makarova; A Mayeda; S H Munroe; J F Cáceres; D G Hayward; A R Krainer
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

View more
  24 in total

1.  The DNA damage response pathway regulates the alternative splicing of the apoptotic mediator Bcl-x.

Authors:  Lulzim Shkreta; Laetitia Michelle; Johanne Toutant; Michel L Tremblay; Benoit Chabot
Journal:  J Biol Chem       Date:  2010-10-27       Impact factor: 5.157

2.  Aberrant splicing of the E-cadherin transcript is a novel mechanism of gene silencing in chronic lymphocytic leukemia cells.

Authors:  Sanjai Sharma; Alan Lichtenstein
Journal:  Blood       Date:  2009-09-10       Impact factor: 22.113

3.  Methylxanthines Increase Expression of the Splicing Factor SRSF2 by Regulating Multiple Post-transcriptional Mechanisms.

Authors:  Jia Shi; Kirk Pabon; Kathleen W Scotto
Journal:  J Biol Chem       Date:  2015-03-28       Impact factor: 5.157

4.  KLF6 loss of function in human prostate cancer progression is implicated in resistance to androgen deprivation.

Authors:  XiaoMei Liu; Alejandro Gomez-Pinillos; Charisse Loder; Enrique Carrillo-de Santa Pau; Ruifang Qiao; Pamela D Unger; Ralf Kurek; Carole Oddoux; Jonathan Melamed; Robert E Gallagher; John Mandeli; Anna C Ferrari
Journal:  Am J Pathol       Date:  2012-07-20       Impact factor: 4.307

5.  A Cytoplasmic RNA Virus Alters the Function of the Cell Splicing Protein SRSF2.

Authors:  Efraín E Rivera-Serrano; Ethan J Fritch; Elizabeth H Scholl; Barbara Sherry
Journal:  J Virol       Date:  2017-03-13       Impact factor: 5.103

6.  Estrogen receptor alpha polymorphisms and the risk of malignancies.

Authors:  Andrei Anghel; Diana Narita; Edward Seclaman; Emilian Popovici; Mariana Anghel; Liviu Tamas
Journal:  Pathol Oncol Res       Date:  2010-04-11       Impact factor: 3.201

7.  Xanthines down-regulate the drug transporter ABCG2 and reverse multidrug resistance.

Authors:  Rui Ding; Jia Shi; Kirk Pabon; Kathleen W Scotto
Journal:  Mol Pharmacol       Date:  2011-11-23       Impact factor: 4.436

8.  Exon 11 skipping of E-cadherin RNA downregulates its expression in head and neck cancer cells.

Authors:  Sanjai Sharma; Wei Liao; Xiaofeng Zhou; David T W Wong; Alan Lichtenstein
Journal:  Mol Cancer Ther       Date:  2011-07-15       Impact factor: 6.261

9.  Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer.

Authors:  Amjad P Khan; Laila M Poisson; Vadiraja B Bhat; Damian Fermin; Rong Zhao; Shanker Kalyana-Sundaram; George Michailidis; Alexey I Nesvizhskii; Gilbert S Omenn; Arul M Chinnaiyan; Arun Sreekumar
Journal:  Mol Cell Proteomics       Date:  2009-11-09       Impact factor: 5.911

10.  Antagonistic factors control the unproductive splicing of SC35 terminal intron.

Authors:  Natacha Dreumont; Sara Hardy; Isabelle Behm-Ansmant; Liliane Kister; Christiane Branlant; James Stévenin; Cyril F Bourgeois
Journal:  Nucleic Acids Res       Date:  2009-12-03       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.